Gatehouse Bio
- Company typePrivate
- Founded2018
- HeadquartersNatick, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Gatehouse Bio firmographics
Firmographics- Name
- Gatehouse Bio
- Legal name
- Gatehouse Bio
- Website
- https://gatehousebio.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Gatehouse Bio industry classification
Industry- Product category
- AI-driven RNA therapeutics platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industry
- Transcriptomics & Gene Expression Profiling Services (HLAGANAE)
Keywords
Where Gatehouse Bio is headquartered
LocationHeadquarters
- HQ city
- Natick
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Gatehouse Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Distribution channels1 record
Marketing channels3 records
Gatehouse Bio product offering
Product offeringCore offering
Gatehouse Bio's core offering is the Code-Breaker™ platform, an AI-powered system that decodes the landscape of small RNAs (sRNAs) and digitally designs biomarker-guided precision oligonucleotide therapeutics. The platform is applied across multiple therapeutic areas including pulmonary, cardiac, neurological, and autoimmune diseases, and Gatehouse Bio is currently advancing lead targets into therapies with plans to move its first lead compound into human clinical trials.
Product overview
Gatehouse Bio offers a single unified AI-powered platform called Code-Breaker™ for decoding small RNAs (sRNAs) and designing biomarker-guided precision oligonucleotide therapeutics. The platform is applied across multiple therapeutic areas including pulmonary, cardiac, neurological, and autoimmune diseases. The company is currently developing its lead targets into therapies, with plans to advance its first lead compound through human clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- Code-Breaker™: AI platform that decodes the landscape of small RNAs (sRNAs) and digitally designs biomarker-guided precision oligonucleotide therapeutics
Products and services
- Code-Breaker™ Platform
Companies that use Gatehouse Bio
Customer profileSegments3 records
Ideal customer profiles2 records
Gatehouse Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature1 record
Gatehouse Bio partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
Gatehouse Bio competitors and assessment
Company assessmentDirect peers
- Alnylam Pharmaceuticals: The leading clinical-stage RNAi therapeutics company, developing siRNA-based oligonucleotide drugs across multiple disease areas. Closely comparable to Gatehouse Bio as a direct RNA therapeutics platform; Gatehouse Bio operates at a much earlier pre-clinical stage.
- Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) therapeutics developer with a broad pipeline and multiple approved drugs. Directly comparable in modality (synthetic oligonucleotides for human therapeutics) and multi-disease strategy to Gatehouse Bio's RNA therapeutics platform.
- Arrowhead Pharmaceuticals: Clinical-stage company developing RNA interference (RNAi) therapeutics across multiple disease areas using proprietary delivery and trigger designs. Comparable as a multi-indication oligonucleotide platform pursuing partnership economics similar to Gatehouse Bio's go-to-market model.
- Wave Life Sciences: Designs stereopure oligonucleotide therapeutics, including RNA-targeting modalities, for neurological and other diseases. Comparable as an oligonucleotide design platform with multi-disease application and an emphasis on precision / patient stratification.
Emerging players
- Deep Genomics: AI-driven company using deep learning to identify novel RNA-targeted drug targets and therapeutic candidates. Highly comparable mission (AI + RNA biology for drug discovery) at a more developed stage than Gatehouse Bio.
- Atomic AI: AI-focused company that combines RNA structural biology with deep learning to discover RNA-targeted small molecules and therapeutics. Comparable in combining AI with RNA biology to design precision medicines.
- Inceptive Therapeutics: AI-native biotech designing RNA-based medicines using deep learning models of RNA biology. Closely comparable to Gatehouse Bio as an AI-first RNA therapeutics platform, though focused on mRNA design rather than sRNA.
Broad incumbents
- Recursion Pharmaceuticals: Larger, publicly listed AI-driven drug discovery company combining high-throughput biology with machine learning to discover therapeutics across many indications. Broader incumbent in the AI drug discovery space that intersects with Gatehouse Bio's platform play.
- Generate Biomedicines: Generative AI platform company designing novel protein and nucleic-acid-based therapeutics. Comparable as a generative-AI-first therapeutics platform with a similar multi-modality ambition.
- Insitro: Machine-learning-driven drug discovery company pairing data generation and predictive models to develop therapeutics. Comparable broader AI-native biotech model, though focused on small molecules and validated target discovery rather than oligonucleotide design.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Gatehouse Bio social profiles
Digital presenceGatehouse Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gatehouse Bio leadership team
Management profileNumber of profiles
Profiles1 record
Gatehouse Bio funding detail
Funding detailFunding overview
Funding rounds8 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gatehouse Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gatehouse Bio
What does Gatehouse Bio do?
Gatehouse Bio's core offering is the Code-Breaker™ platform, an AI-powered system that decodes the landscape of small RNAs (sRNAs) and digitally designs biomarker-guided precision oligonucleotide therapeutics. The platform is applied across multiple therapeutic areas including pulmonary, cardiac, neurological, and autoimmune diseases, and Gatehouse Bio is currently advancing lead targets into therapies with plans to move its first lead compound into human clinical trials.
Is Gatehouse Bio a public or private company?
Gatehouse Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Gatehouse Bio founded?
Gatehouse Bio was founded in 2018. It employs 11 to 50 people.
Where is Gatehouse Bio based?
Gatehouse Bio is headquartered in Natick, United States, in the North America region.
Who are Gatehouse Bio's main competitors?
Direct peers on record are Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals and Wave Life Sciences. Emerging players are Deep Genomics, Atomic AI and Inceptive Therapeutics. Broad incumbents are Recursion Pharmaceuticals, Generate Biomedicines and Insitro.
Does Gatehouse Bio have an API?
No public API is recorded for Gatehouse Bio.
What industry is Gatehouse Bio in?
Gatehouse Bio's product category is AI-driven RNA therapeutics platform. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 541714 and its SIC code is 8731.